PA
EWTX icon

Parallel Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Parallel Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.5K Buy
1,513
+481
+47% +$16.6K ﹤0.01% 2004
2026
Q1 		$32.5K Buy
1,032
+406
+65% +$11.7K ﹤0.01% 2238
2025
Q4 		$15.5K Buy
626
+531
+559% +$10.7K ﹤0.01% 2431
2025
Q3 		$1.54K Hold
95
– – ﹤0.01% 3118
2025
Q2 		$1.25K Sell
95
-38
-29% -$548 ﹤0.01% 3151
2025
Q1 		$2.93K Sell
133
-3
-2% -$79 ﹤0.01% 2861
2024
Q4 		$3.63K Buy
136
+3
+2% +$96 ﹤0.01% 2756
2024
Q3 		$3.55K Hold
133
– – ﹤0.01% 2723
2024
Q2 		$2.4K Buy
133
+38
+40% +$663 ﹤0.01% 2763
2024
Q1 		$1.73K Hold
95
– – ﹤0.01% 2845
2023
Q4 		$1.04K Buy
+95
New +$667 ﹤0.01% 2925
2023
Q3 		– Sell
-296
Closed -$2.29K – 3404
2023
Q2 		$2.29K Buy
296
+219
+284% +$1.85K ﹤0.01% 2716
2023
Q1 		$514 Buy
+77
New +$714 ﹤0.01% 3114

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors's EWTX Position: Q2 2026 in Review

Parallel Advisors increased its Edgewise Therapeutics (EWTX) stake by 47% in Q2 2026, buying an estimated $16.6K and bringing the position to 1,513 shares worth $61.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Parallel Advisors first reported a position in EWTX in Q1 2023 and has held it in 13 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Parallel Advisors held 1,513 shares of Edgewise Therapeutics worth $61.5K as of Q2 2026.
  • Parallel Advisors bought 481 Edgewise Therapeutics shares in Q2 2026, an estimated $16.6K.
  • Edgewise Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2004 holding.
  • Parallel Advisors first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.